• NeuroOne Medical Technologies held its annual shareholder meeting on April 3, 2026.
• Shareholders elected Jeffrey Mathiesen, Edward Andrle as Class III directors.
• Baker Tilly US was ratified as independent auditor for fiscal year ending Sept. 30, 2026.
• Investors authorized a reverse stock split, with ratio to be set by board in range of 1-for-2 to 1-for-15.
• Holders adopted an amendment to 2025 Equity Incentive Plan, also authorized adjournments to solicit additional proxies if needed to pass reverse split item.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neuroone Medical Technologies Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-039992), on April 03, 2026, and is solely responsible for the information contained therein.